State Street’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-62,236
| Closed | -$43.5K | – | 4780 |
|
|
2023
Q1 | $43.5K | Hold |
62,236
| – | – | ﹤0.01% | 4537 |
|
|
2022
Q4 | $56K | Hold |
62,236
| – | – | ﹤0.01% | 4535 |
|
|
2022
Q3 | $373K | Buy |
62,236
+19,200
| +45% | +$109K | ﹤0.01% | 3883 |
|
|
2022
Q2 | $178K | Hold |
43,036
| – | – | ﹤0.01% | 4266 |
|
|
2022
Q1 | $164K | Buy |
43,036
+7,176
| +20% | +$32.3K | ﹤0.01% | 4456 |
|
|
2021
Q4 | $161K | Buy |
35,860
+17,450
| +95% | +$88.6K | ﹤0.01% | 4438 |
|
|
2021
Q3 | $86K | Hold |
18,410
| – | – | ﹤0.01% | 4581 |
|
|
2021
Q2 | $130K | Sell |
18,410
-173,477
| -90% | -$935K | ﹤0.01% | 4316 |
|
|
2021
Q1 | $1.13M | Buy |
191,887
+14,579
| +8% | +$88.3K | ﹤0.01% | 3593 |
|
|
2020
Q4 | $817K | Buy |
177,308
+16,200
| +10% | +$69.8K | ﹤0.01% | 3590 |
|
|
2020
Q3 | $627K | Buy |
161,108
+23,878
| +17% | +$480K | ﹤0.01% | 3540 |
|
|
2020
Q2 | $3.95M | Buy |
137,230
+68,269
| +99% | +$1.58M | ﹤0.01% | 2881 |
|
|
2020
Q1 | $1.48M | Buy |
68,961
+28,068
| +69% | +$637K | ﹤0.01% | 3187 |
|
|
2019
Q4 | $805K | Buy |
+40,893
| New | +$581K | ﹤0.01% | 3446 |
|
State Street's STSA Position: Q2 2023 in Review
State Street sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 62,236 shares — an estimated $43.5K sold.
State Street first reported a position in STSA in Q4 2019 and held it in 14 quarters. The position peaked at $3.95M in Q2 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.
- State Street reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- State Street sold 62,236 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $43.5K.
- State Street first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 14 quarters.
- State Street's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $3.95M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.
Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.